Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.

doi:10.1158/1078-0432.CCR-14-0857

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2015

Bohanes Pierre, Rankin Cathryn J, Blanke Charles D, Winder Thomas, Ulrich Cornelia M, Smalley Stephen R, Rich Tyvin A, Martensen James A, Benson Al B, Mayer Robert J, Cripps Christine M, Danenberg Kathleen, Makar Karen W, Zhang Wu, Benedetti Jacqueline K, Lenz Heinz-Josef

Abstract excerpt

PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Disease-Free Survival

Share to Fluorouracil

Share to Glutathione S-Transferase pi

Share to Kaplan-Meier Estimate

Share to Polymorphism, Restriction Fragment Length

Share to Rectal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25589620
DOI: 10.1158/1078-0432.CCR-14-0857
PMCID: PMC4566931

Genes

GSTP1
CXCR2
EGF
EGFR
ERCC1
FGFR4
ICAM1
MMP3
RAD51
XRCC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.PMID 25589620Read ↗

IL1B rs1143634 Genotype Identifies Differential Cancer-Specific Survival by Neoadjuvant Strategy in Locally Advanced Rectal Cancer: A Prospective Randomized TrialSemantic proximity Read ↗

Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.Semantic proximity Read ↗

Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.Semantic proximity Read ↗

Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische OnkologieSemantic proximity Read ↗

Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.Semantic proximity Read ↗

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.Semantic proximity Read ↗

A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.Semantic proximity Read ↗

Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.Semantic proximity Read ↗

Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancerSemantic proximity Read ↗

Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.Semantic proximity Read ↗

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.Semantic proximity Read ↗

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.